Match!
Albertus H. de Boer
VU University Amsterdam
648Publications
62H-index
16.2kCitations
Publications 655
Newest
#2Frits M.E. Franssen (Maastricht University Medical Centre)H-Index: 29
Last.F. de Vries (UM: Maastricht University)H-Index: 34
view all 7 authors...
Abstract Aims C-reactive protein (CRP) is an important biomarker in systemic inflammation in COPD; reports have suggested inhaled corticosteroids (ICS) attenuate CRP levels. We evaluated the risk of moderate-to-severe exacerbations, severe exacerbations and all-cause mortality among patients with COPD currently exposed to Inhaled corticosteroids (ICS) stratified by CRP levels compared to never ICS users with low CRP levels. Methods We included subjects age 40 or more who had a diagnosis of COPD ...
Source
#2Linda DonkerbroekH-Index: 1
Last.Bart J. F. van den Bemt (Radboud University Nijmegen)H-Index: 16
view all 6 authors...
1 CitationsSource
#1Emilie Gieling (UU: Utrecht University)H-Index: 2
#2F. de Vries (UM: Maastricht University)H-Index: 34
Last.Andrea M. Burden (UM: Maastricht University)H-Index: 2
view all 8 authors...
Background As an alternative to vitamin K antagonist and low-dose aspirin ( 2). Conclusion Non vitamin K oral anticoagulants are associated with a higher risk on all-cause mortality, particularly in men and in patients with higher stroke risk.
Source
#1Rianne A. Weersink (UG: University of Groningen)H-Index: 3
#2Marianna Abadier (UU: Utrecht University)
Last.Sander D. Borgsteede (Erasmus University Medical Center)H-Index: 14
view all 5 authors...
Source
Source
#1Daniel M.F. Claassens (UMCG: University Medical Center Groningen)H-Index: 1
#2Gerrit J. A. Vos (UMCG: University Medical Center Groningen)H-Index: 1
Last.Jurriën M. ten Berg (UMCG: University Medical Center Groningen)H-Index: 52
view all 20 authors...
Abstract Background It is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors. Methods We conducted ...
14 CitationsSource
#1Rafael Dal-Ré (UAM: Autonomous University of Madrid)H-Index: 28
Last.John P. A. Ioannidis (Stanford University)H-Index: 151
view all 7 authors...
Abstract Objectives European regulations do not allow modification or waiver of informed consent for medicines randomized controlled trials (RCTs) where the three 2016 Council for International Organizations of Medical Sciences (CIOMS) provisions are met (consent would be impractical or unfeasible, yet the trial would have high social value and pose no or minimal risk to participants). We aimed to identify whether any such trials of medicines were being conducted in Europe. Study Design and Sett...
Source
#1Florence van HunselH-Index: 14
#2Helga Gardarsdottir (UU: Utrecht University)H-Index: 13
view all 4 authors...
Source
#1Mohammad Bakhriansyah (Lambung Mangkurat University)H-Index: 1
#2Ronald H. B. Meyboom (UU: Utrecht University)H-Index: 24
Last.Olaf H. Klungel (UU: Utrecht University)H-Index: 48
view all 5 authors...
Source
Source
12345678910